Reports Q1 revenue $144.87M, consensus $141.38M. “We continued to deliver strong growth for CAPLYTA in the first quarter,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “We also achieved a significant milestone in our adjunctive MDD program with positive Phase 3 Study 501 results, further advancing our vision for CAPLYTA as a drug of choice across mood disorders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular Therapies Reports First Quarter 2024 Financial Results
- Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
- Biotech Sector: M&A Fuels Renewed Excitement
- Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Intra-Cellular price target raised to $107 from $100 at Canaccord
